Logo image of BHVN

BIOHAVEN LTD (BHVN) Stock Fundamental Analysis

USA - NYSE:BHVN - VGG1110E1079 - Common Stock

15.81 USD
+0.3 (+1.93%)
Last: 10/3/2025, 8:25:17 PM
16.12 USD
+0.31 (+1.96%)
After Hours: 10/3/2025, 8:25:17 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BHVN. BHVN was compared to 536 industry peers in the Biotechnology industry. The financial health of BHVN is average, but there are quite some concerns on its profitability. BHVN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.
BHVN had a negative operating cash flow in the past year.
In the past 5 years BHVN always reported negative net income.
BHVN had a negative operating cash flow in each of the past 5 years.
BHVN Yearly Net Income VS EBIT VS OCF VS FCFBHVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

BHVN's Return On Assets of -139.34% is on the low side compared to the rest of the industry. BHVN is outperformed by 83.96% of its industry peers.
BHVN's Return On Equity of -569.87% is on the low side compared to the rest of the industry. BHVN is outperformed by 78.73% of its industry peers.
Industry RankSector Rank
ROA -139.34%
ROE -569.87%
ROIC N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
BHVN Yearly ROA, ROE, ROICBHVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

BHVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHVN Yearly Profit, Operating, Gross MarginsBHVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for BHVN has been increased compared to 1 year ago.
The number of shares outstanding for BHVN has been increased compared to 5 years ago.
BHVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BHVN Yearly Shares OutstandingBHVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BHVN Yearly Total Debt VS Total AssetsBHVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

BHVN has an Altman-Z score of -6.12. This is a bad value and indicates that BHVN is not financially healthy and even has some risk of bankruptcy.
BHVN has a worse Altman-Z score (-6.12) than 65.67% of its industry peers.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.12
ROIC/WACCN/A
WACCN/A
BHVN Yearly LT Debt VS Equity VS FCFBHVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 3.82 indicates that BHVN has no problem at all paying its short term obligations.
The Current ratio of BHVN (3.82) is comparable to the rest of the industry.
BHVN has a Quick Ratio of 3.82. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.
BHVN has a Quick ratio of 3.82. This is comparable to the rest of the industry: BHVN outperforms 46.83% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 3.82
BHVN Yearly Current Assets VS Current LiabilitesBHVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 16.28% over the past year.
EPS 1Y (TTM)16.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BHVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.51% on average per year.
Based on estimates for the next years, BHVN will show a very strong growth in Revenue. The Revenue will grow by 179.60% on average per year.
EPS Next Y15.79%
EPS Next 2Y16.54%
EPS Next 3Y15.07%
EPS Next 5Y14.51%
Revenue Next Year-31.41%
Revenue Next 2Y286.58%
Revenue Next 3Y247.8%
Revenue Next 5Y179.6%

3.3 Evolution

BHVN Yearly Revenue VS EstimatesBHVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
BHVN Yearly EPS VS EstimatesBHVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHVN Price Earnings VS Forward Price EarningsBHVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHVN Per share dataBHVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

BHVN's earnings are expected to grow with 15.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.54%
EPS Next 3Y15.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHAVEN LTD

NYSE:BHVN (10/3/2025, 8:25:17 PM)

After market: 16.12 +0.31 (+1.96%)

15.81

+0.3 (+1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners82.82%
Inst Owner Change7.92%
Ins Owners11.13%
Ins Owner Change0%
Market Cap1.67B
Analysts87.5
Price Target47.19 (198.48%)
Short Float %14.1%
Short Ratio5.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.05%
Min EPS beat(2)-25.54%
Max EPS beat(2)-0.56%
EPS beat(4)1
Avg EPS beat(4)-9.91%
Min EPS beat(4)-25.54%
Max EPS beat(4)1.84%
EPS beat(8)1
Avg EPS beat(8)-26.79%
EPS beat(12)3
Avg EPS beat(12)-26.01%
EPS beat(16)3
Avg EPS beat(16)-32.21%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.92%
PT rev (3m)-15.05%
EPS NQ rev (1m)0.63%
EPS NQ rev (3m)-0.74%
EPS NY rev (1m)-1.06%
EPS NY rev (3m)-2.29%
Revenue NQ rev (1m)-9.09%
Revenue NQ rev (3m)-32.93%
Revenue NY rev (1m)-15.38%
Revenue NY rev (3m)-67.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.43
P/tB 14.57
EV/EBITDA N/A
EPS(TTM)-7.66
EYN/A
EPS(NY)-6.03
Fwd EYN/A
FCF(TTM)-6.11
FCFYN/A
OCF(TTM)-6.1
OCFYN/A
SpS0
BVpS1.27
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -139.34%
ROE -569.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 3.82
Altman-Z -6.12
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.45%
Cap/Depr(5y)891.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.7%
EPS Next Y15.79%
EPS Next 2Y16.54%
EPS Next 3Y15.07%
EPS Next 5Y14.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-31.41%
Revenue Next 2Y286.58%
Revenue Next 3Y247.8%
Revenue Next 5Y179.6%
EBIT growth 1Y-2.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.68%
EBIT Next 3Y6.45%
EBIT Next 5Y12.94%
FCF growth 1Y-116.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-120.16%
OCF growth 3YN/A
OCF growth 5YN/A